Mahoney S.,Curtin University Australia |
Arfuso F.,University of Western Australia |
Rogers P.,University of Western Australia |
Hisheh S.,University of Melbourne |
And 3 more authors.
Journal of Biosciences | Year: 2012
Phenoxodiol is an isoflavone derivative that has been shown to elicit cytotoxic effects against a broad range of human cancers. We examined the effect of phenoxodiol on cell death pathways on the prostate cell lines LNCaP, DU145 and PC3, representative of different stages of prostate cancer, and its effects on cell death pathways in these cell lines. Cell proliferation assays demonstrated a significant reduction in the rate of cell proliferation after 48 h exposure to phenoxodiol (10 and 30 μM). FACS analysis and 3′-end labelling indicated that all three prostate cancer cell lines underwent substantial levels of cell death 48 h after treatment. Mitochondrial membrane depolarization, indicative of early-stage cell death signalling, using JC-1 detection, was also apparent in all cell lines after exposure to phenoxodiol in the absence of caspase-3 activation. Caspase inhibition assays indicated that phenoxodiol operates through a caspase-independent cell death pathway. These data demonstrate that phenoxodiol elicits anti-cancer effects in prostate cancer cell lines representative of early and later stages of development through an as-yet-unknown cell death mechanism. These data warrant the further investigation of phenoxodiol as a potential treatment for prostate cancer. © 2011 Indian Academy of Sciences. Source
Kelly G.,Novogen |
Mor G.,Yale University
European Pharmaceutical Review | Year: 2014
A consensus panel convened by the American Association of Cancer Research in 2006 defined a cancer stem cell (CSC) as "a cell within a tumour that possesses the capacity to self-renew and to cause the heterogeneous lineages of cancer cells that comprise the tumour1." Eight years on, the role of the CSC in cancer biology remains only marginally better defined. There is little argument that many, if not most, tumour phenotypes are heterogeneous tissues comprised of a spectrum of cells of variable phenotype, genotype and behaviour. Source
Novogen | Date: 2011-06-17
This invention relates to natural products containing phyto-oestrogens, or phyto-oestrogen analogues, which have various beneficial physiological effects in man, and which have a variety of uses, such as to promote good health and as a dietary additive, for example. The invention describes a method of improving the health of a human by administering to the human a health supplementing amount of a phyto-oestrogen selected from genistein, daidzein formononentin and/or biochanin A. A health supplement comprising a health supplementary amount of a phyto-oestrogen selected from genisten daidzein formononentin and/or biochanin A, is also described. Preferably, the supplement also comprises at least one dietary suitable excipient, diluent, carrier or food, and may be in the form of a tablet or capsule, for example. Ideally, the phyto-oestrogen is extracted from red clover or from soya, although any source rich in isoflavones may also be used. The supplement can be used to prevent or ameliorate such conditions as breast cancer, benign breast disease, pre-menstrual syndrome, or symptoms associated with menopause in women, or various types of cancer, and especially for high blood cholesterol levels in all humans, for instance.
Novogen | Date: 2014-03-18
Pharmaceutical preparations; anti-cancer pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; compounds for treating cancer. Scientific research services; research to develop new products; advisory services relating to scientific research; biotechnology research; medical research; chemical research.
Novogen | Date: 2014-07-04
Anti-cancer pharmaceutical preparations; pharmaceutical preparations; pharmaceutical preparations for the treatment of cancer; compounds for treating cancer; therapeutic agents (medical); therapeutic drugs (medical).